Taysha Gene Therapies (TSHA) Tops Q1 EPS by 8c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 EPS of ($0.28), $0.08 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $4.71 million versus the consensus estimate of $0 .

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Redburn upgrades Southwest, stays bullish on Delta and United